Abstract
Functional alterations in synaptic contacts in specific brain areas are a hallmark of major depressive disorder (MDD). Antidepressant treatments not only readjust the aberrant concentrations of neurotransmitters in the synaptic clefts, but have the capacity to reshape neuronal circuits by affecting synaptogenesis and synaptic stabilization in specific regions of the brain. Nevertheless, the underlying molecular mechanisms are still unclear. Glial cells are active partners of neurons in orchestrating molecular signals that regulate the arrangement of neuronal circuits both in the developing and adult brain. Here, we present evidences indicating that glial cells might be substrates of antidepressant action for restructuring neuronal networks that has become miswired after the onset or progression of MDD. We aim to offer an alternative approach (a “gliocentric” view) to study this complex neuropsychiatric disorder and to identify alternative mechanisms of action for the currently available antidepressant therapies. Such knowledge may help to improve current treatment regimens or identify novel targets for the development of more efficacious antidepressant drugs.
Keywords: Astrocyte, major depressive disorder, microglia, mood disorder, synaptic plasticity.
Current Drug Targets
Title:Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Volume: 14 Issue: 11
Author(s): Barbara Di Benedetto, Rainer Rupprecht and Boldizsár Czéh
Affiliation:
Keywords: Astrocyte, major depressive disorder, microglia, mood disorder, synaptic plasticity.
Abstract: Functional alterations in synaptic contacts in specific brain areas are a hallmark of major depressive disorder (MDD). Antidepressant treatments not only readjust the aberrant concentrations of neurotransmitters in the synaptic clefts, but have the capacity to reshape neuronal circuits by affecting synaptogenesis and synaptic stabilization in specific regions of the brain. Nevertheless, the underlying molecular mechanisms are still unclear. Glial cells are active partners of neurons in orchestrating molecular signals that regulate the arrangement of neuronal circuits both in the developing and adult brain. Here, we present evidences indicating that glial cells might be substrates of antidepressant action for restructuring neuronal networks that has become miswired after the onset or progression of MDD. We aim to offer an alternative approach (a “gliocentric” view) to study this complex neuropsychiatric disorder and to identify alternative mechanisms of action for the currently available antidepressant therapies. Such knowledge may help to improve current treatment regimens or identify novel targets for the development of more efficacious antidepressant drugs.
Export Options
About this article
Cite this article as:
Benedetto Di Barbara, Rupprecht Rainer and Czéh Boldizsár, Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/1389450111314110011
DOI https://dx.doi.org/10.2174/1389450111314110011 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface [Hot Topic: Rational Drug Design and The Discovery of the 1,2,3-Triazolines as a Unique Class of Anticonvulsants and Antiischemic Agents (Guest Editor: Pankaja K. Kadaba)]
Current Medicinal Chemistry Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases
Current Molecular Medicine Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Chromen-1-phenylpropan-1-one Derivatives and their Antidepressant/ Anticonvulsant Activities
Letters in Drug Design & Discovery Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets A Review on Synthesis of Benzothiazole Derivatives
Current Organocatalysis Somatic Genome Variations in Health and Disease
Current Genomics Fluorinated Molecules as Drugs and Imaging Agents in the CNS
Current Topics in Medicinal Chemistry A Comprehensive Investigation of Molecular Signatures and Pathways Linking Alzheimer’s Disease and Epilepsy <i>via</i> Bioinformatic Approaches
Current Alzheimer Research Common Genetic Variants of the Mitochondrial Trafficking System and Mitochondrial Uncoupling Proteins Affect the Development of Two Slowly Developing Demyelinating Disorders, Leukoaraiosis and Multiple Sclerosis
Current Medicinal Chemistry Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders N-Valproyl-L-Phenylalanine as New Potential Antiepileptic Drug: Synthesis, Characterization and In Vitro Studies on Stability, Toxicity and Anticonvulsant Efficacy
Medicinal Chemistry Preface
Current Drug Targets - CNS & Neurological Disorders Pharmacological Approaches of Binge Drinking
Current Pharmaceutical Design Genetic Studies on the Role of T-Type Ca2+ Channels in Sleep and Absence Epilepsy
CNS & Neurological Disorders - Drug Targets Dynorphin Convertases and their Functions in CNS
Current Pharmaceutical Design New Perspectives on the Structure and Function of the Na+ Channel Multigene Family
Current Medicinal Chemistry - Central Nervous System Agents Role of Protein Tyrosine Phosphatases in Plants
Current Genomics New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry